Semaglutide mechanism of action.

Semaglutide (Novo Nordisk development code NN9535) is a 31-residue peptide analogue of human GLP-1(7–37). Two engineered modifications define its pharmacology: an α-aminoisobutyric acid (AIB) substitution at position 8 that blocks proteolytic cleavage by dipeptidyl-peptidase-4, and a C18 fatty-diacid attached to Lys26 through a γ-glutamate–2×OEG linker that promotes reversible binding to serum albumin (Lau et al., 2015; Knudsen & Lau, 2019).

Semaglutide is a selective full agonist at the glucagon-like peptide-1 receptor (GLP-1R), a class-B secretin-family G-protein-coupled receptor. It does not engage the GIP or glucagon receptors at any pharmacologically meaningful concentration — a defining contrast with the dual and triple incretin peptides tirzepatide and retatrutide (Drucker, 2018).

The albumin-binding tail extends the plasma half-life to approximately 165 hours, supporting the once-weekly dosing regimen reported in the clinical literature (Lau et al., 2015). The lipid moiety itself does not contribute to receptor engagement; the receptor pharmacology is driven entirely by the peptide backbone.

The GLP-1 receptor is a class-B GPCR expressed on pancreatic β-cells, on neurons in the hypothalamus and brainstem (including the area postrema and nucleus of the solitary tract), and in gastric, cardiovascular and immune tissues. Its natural ligand is GLP-1(7–37) — an incretin released from intestinal L-cells in response to nutrient intake (Campbell & Drucker, 2013).

Structurally, GLP-1R has a large N-terminal extracellular domain that binds the C-terminal helix of the agonist and a seven-transmembrane bundle that engages the peptide N-terminus to initiate signalling. Dominant downstream coupling is via the stimulatory Gαs protein, activation of adenylyl cyclase, and elevation of intracellular cyclic AMP. Downstream effectors include PKA and EPAC (Drucker, 2018).

Semaglutide engages GLP-1R with sub-nanomolar potency and behaves as a full agonist for cAMP accumulation relative to GLP-1(7–37) (Lau et al., 2015). The AIB-8 substitution preserves the N-terminal receptor-interacting residues while preventing DPP-4 cleavage between His7 and Ala8 — enzymatic degradation that would otherwise inactivate the peptide within minutes of administration.

The C18 fatty-diacid at Lys26 sits away from the receptor-binding face. In-vitro displacement studies show that the acylation does not meaningfully alter receptor affinity but does reduce the free (non-albumin-bound) fraction of peptide available to bind GLP-1R at any given moment — a slow-release effect that supports sustained receptor engagement across the dosing interval (Knudsen & Lau, 2019).

In GLP-1R-expressing cell lines, semaglutide drives a full-agonist cAMP dose-response with potency in the low nanomolar to sub-nanomolar range depending on assay format. cAMP elevation is the primary read-out used in laboratory characterisation of the peptide's mechanism, and single-receptor GLP-1R-expressing HEK293 or CHO systems are the standard reporter platform (Nauck et al., 2021).

Downstream, PKA phosphorylates β-cell substrates including IP3 receptors and voltage-gated Ca²⁺ channels, while EPAC2 potentiates Ca²⁺-triggered exocytosis of insulin granules. Because these steps are downstream of cAMP, they are shared with tirzepatide's GLP-1R arm and with retatrutide's GLP-1R arm — the mechanistic differentiation between the three peptides lives upstream, at the receptor complement, not downstream at the second messenger.

In pancreatic β-cell research models, semaglutide potentiates glucose-stimulated insulin secretion in a glucose-dependent manner: the response is negligible at low ambient glucose and rises steeply as glucose approaches physiological thresholds. This is the classical incretin effect and it is receptor-mediated, not concentration-driven (Campbell & Drucker, 2013). Discussion here is limited to reported laboratory characterisation.

Semaglutide does not engage the glucagon receptor. Reported reductions in glucagon secretion at hyperglycaemia are indirect and attributed to paracrine effects of GLP-1R activation on the pancreatic islet — including β-cell somatostatin release from δ-cells and the local insulin milieu (Drucker, 2018). This contrasts sharply with retatrutide's direct GCGR pharmacology, discussed in the retatrutide mechanism reference.

Semaglutide slows gastric emptying through central and vagal GLP-1R-mediated pathways. Reported effects on gastric-emptying rate diminish with continued exposure — a tachyphylaxis pattern well described for GLP-1R agonists — while the central satiety pathway persists. Gabery et al. (2020) mapped semaglutide-responsive neurons across circumventricular organs and downstream hypothalamic targets in rodents, framing the neural circuitry that underlies reported appetite effects.

The GLP-1 receptor is the founding target of the incretin therapeutic class and the mechanistic reference point against which every dual and triple agonist is characterised. Semaglutide sets the standard for selective GLP-1R pharmacology: a well-behaved full agonist, extensively profiled in the literature, and a natural comparator peptide in any receptor-panel experiment (Nauck et al., 2021).

For laboratory research, selective GLP-1R agonism means a single-receptor assay is sufficient to characterise semaglutide's activity. That simplicity is both an experimental advantage — fewer variables, cleaner data — and a limitation, because the peptide does not exercise the two- or three-receptor assay coverage required for dual and triple agonists.